1Q13 Conference Call Presentation

May 15, 2013

• Gross revenues of R$814.7 million, an increase of 16.5% over 1Q12.

• Total SSS (same-store sales) of 10.8%, with 4.3% for mature stores

• Adjusted EBITDA of R$34.8 million, with adjusted EBITDA margin of 4.3%

• Adjusted net income of R$2.6 million, with adjusted net margin of 0.3%

• Reinforcement of regional presence on a country-wide scale: With the opening of 9 new owned

stores and 19 franchisees, we ended 1Q13 with a base of 1.115 stores.

• Conclusion of Big Ben & Guararapes corporate integration

243 Owned stores¹

122 Owned stores

133 Owned stores

406 Franchises

211 Owned stores

Source: Brasil Pharma

709 Owned stores

406 Franchises

1,115 stores

REGIONS

Owned stores

North 118

Northeast 249

Midwest 131

Southeast

South 211

12

1

114 20

15

25

13

201

7

72

122

1

10

5 Distribution centers

93

2

National Footprint

9 openings in 1Q13 (+ 8 closings)

39.9% not yet at mature stage

1- Includes 12 stores of the Guararapes drugstore chain.

1

12.0%

17.8%

10.2%60.1%

Stores with less than 12 months

Stores with 12 to 24 months

Stores with 24 to 36 months

Stores with more than 36 months

Hering Grupo Pãode Açucar

LojasAmericas

MagazineLuiza

RaiaDrogasil IMC Renner BRPH Marisa

1Q12 1Q13

699.3

814.7

1Q12 1Q13

1Q12 1Q13

1Q12 1Q13

Generic penetration in medicine sales

37.5% 36.5% 37.1% 38.4% 37.9%

16.4% 17.1% 17.0% 16.4% 16.5%

46.1% 46.4% 45.9% 45.2% 45.6%

1Q12 2Q12 3Q12 4Q12 1Q13

Non-medicinesGeneric MedicineBranded medicine

Lower demand barred price adjustments

1Q12 1Q13

Higher competition in some of the regions we operate

1Q12 1Q13

Sales expenses SG&A total

1Q12 1Q13

G&A % Sales expenses % SG&A total %

1Q12 2012 1Q13

Proforma Proforma

Gross Revenues 699,349 3,094,293 814,653

General and administrative expenses (G&A) (51,464) (206,540) (46,501)

% Gross Revenues 7.4% 6.7% 5.7%

G&A Dilution (R$'000)

-50.0%

-40.0%

-30.0%

-20.0%

-10.0%

0.0%

10.0%

1Q12 1Q13

-50%

-40%

-30%

-20%

-10%

00%

10%

20%

30%

1Q12 1Q13

1Q12 1Q13

Proforma

Non recurring SG&A 16,726 (5,410)

IPO /Debenture issuance expenses (108)

Stock Option Plan (SOP) (1,508) (2,816)

M&A/Branding (1,807) (684)

Income related to Santana insurance 21,653

Platforms Integration/Downsizing (1,504) (1,763)

Other (147)

Non recurring expenses (R$'000)

Cash position and indebtedness (R$'000) 1Q12 4Q12 1Q13

(+) Loans and financing 344,487 177,049 169,079

Short term 241,251 83,229 44,864

Long term 103,236 93,820 124,215

(+) Debentures - 253,642 258,937

Short term - 5,237 10,427

Long term - 248,405 248,510

(+) Accounts payable for investment acquisition 347,212 345,333 264,430

Short term 34,833 99,711 82,833

Long term 312,379 245,622 181,597

(=) Total Indebtedness 691,699 776,024 692,446

Short term (%) 39.9% 24.2% 19.9%

Long term (%) 60.1% 75.8% 80.1%

(-) Cash and cash equivalents (122,901) (368,751) (183,870)

(=) Net Debt 568,798 407,273 508,576

Net debt/Adjusted EBITDA (LTM) 3.4 X 2.1 X 2.7 X

Working capial 4Q11 1Q12 4Q12 1Q13

Accounts receivable 21 22 23 24

Inventories 114 86 95 106

Suppliers 62 63 58 55

Working capital in days 72 45 60 75

Cash flow Statement (R$'000) 1Q12 1Q13

EBT 10,226 (7,553)

(+) Depreciation and amortization 16,092 16,462

(+) Others 13,142 24,389 -

Operating cash generation 39,460 33,298

(+) Change in working capital (57,533) (83,142)

(+) Change in other non current assets and liabilities (13,918) (13,781)

Cash consumption (71,451) (96,923)

Net cash generated by operating activities (31,991) (63,624)

(-) Capex from operations (19,547) (24,922)

(-) Acquisitions (286,332) (80,903)

Net Cash from investing activities (305,879) (105,825)

(+/-) Loans and financing 196,275 (15,431)

(+) Equity funding 941 -

Net Cash from financing activities 197,216 (15,431)

Change in cash and cash equivalents (140,654) (184,881)

Cash and cash equivalents - opening balance 263,555 368,751

Cash and cash equivalents - closing balance 122,901 183,870

• One more step into the process of cultural integration: dissemination of a unique and national culture

to our more than 17 thousand employees;

• Endorsement: the storefront of the totality of our owned stores now carries Brasil Pharma’s

endorsement;

• Our regional brands remains, but now have beside them the name of a strong Comapany that Brazil

already knows and trusts

1

2

CSC – Back-office of Stores & Corporate

Commercial – Procurement & Logistics

PDV – Front store 3

SAP – Worldwide presence

(1.000 largest companies)

Retail 79%

Wholesale 69%

Pharma Industry 100%

Implementation Phases:

Phase 1 - 2013: Financing and Accounting

Phase 2 - 2014: Procurement Department – Purchase and Logistics (under analysis)

Jun-1

1

Jul-11

Aug-1

1

Sep-1

1

Oct-

11

Nov-1

1

Dec-1

1

Jan-1

2

Fe

b-1

2

Ma

r-12

Apr-

12

May-1

2

Jun-1

2

Jul-12

Aug-1

2

Oct-

12

Nov-1

2

Dec-1

2

Jan-1

3

Fe

b-1

3

Mar-

13

Brasil Pharma IBOV

Source: Bloomberg, as of March 31st, 2013.

Company’s IPO on June 24, 2011.